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Lung cancerAbstract Chitosan is a linear polysaccharide and non-toxic bioactive polymer with a wide variety
of applications due to its functional properties such as ease of modification, and biodegradability.
In this study, a green protocol for supporting of Cu(II) on chitosan-encapsulated magnetic Fe3O4
nanoparticles is described. The morphological and physicochemical features of the material were
determined using several advanced techniques like fourier transformed infrared spectroscopy
(FT-IR), field emission scanning electron microscopy (FESEM), transmission electron microscopy
(TEM), energy dispersive X-ray spectroscopy (EDS), X-ray diffraction (XRD), inductively coupled
plasma (ICP), vibrating sample magnetometer (VSM) and X-ray photoelectron spectroscopy
2 Z. Shi et al.(XPS). The average diameter of the NPs was approximately 15–25 nm. In addition, the Fe3O/CS/Cu
(II) nanocomposite was engaged in biological assays like study of anti-oxidant properties by DPPH
mediated free radical scavenging test using BHT as a reference molecule. Thereafter, on having a
significant IC50 value in radical scavenging assay, we extended the bio-application of the desired
nanocomposite in anticancer study of lung well-differentiated bronchogenic adenocarcinoma, lung
moderately differentiated adenocarcinoma, and lung poorly differentiated adenocarcinoma of
human lung in-vitro conditions. In the cytotoxicity and anti-human lung studies, the nanocomposite
was treated to lung cancer lung well-differentiated bronchogenic adenocarcinoma (HLC-1), lung
moderately differentiated adenocarcinoma (LC-2/ad), and lung poorly differentiated adenocarci-
noma (PC-14) cell line following MTT assay. The cell viability of malignant lung cell line reduced
dose-dependently in the presence of Fe3O/CS/Cu(II) nanocomposite. The recent results suggest that
Fe3O/CS/Cu(II) nanocomposite have a suitable anticancer activity against lung cell lines.
 2021 Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In human respiratory system lung is an imperative organ that
is actively involved in the crucial transfusion of O2 and CO2
into blood (World Cancer Research Fund and American
Institute for Cancer Research, 2007; Thun et al., 2018). Impro-
per functioning of lungs majorly occurs due to flu, asthma,
bronchitis, pneumonia, tuberous sclerosis, cystic fibrosis,
chronic obstructive pulmonary disease (COPD), tuberculosis,
emphysema and cancer. Lung cancer is one of the most inva-
sive and metastasizing cancer and one of the major reason of
mortality in the world. It is the third most common cancers
after breast and prostate in terms of fatality and affects both
men and women (Alaoui et al., 2015). The common symptoms
for lung cancer are weakness, loss of weight, fatigue, coughing
up blood, hoarseness, wheezing, chest pain and dysphagia
(Hecht, 2012; Alsharairi, 2019). Chemotherapy, radio therapy,
targeted therapy, immunotherapy and surgery are the general
therapeutic treatments for lung cancer patients (Jones and
Baldwin, 2018). Nevertheless, due to severe side effects of the
treatment procedures like damage of nerves, toxicity, hair loss,
fatigue, diarrhea and mouth sore, it has been a serious concern
among the researchers to find out new formulations (Stahl,
2013). While searching for unconventional remedies, it has
been found that metal nanoparticles (MNP), being tender to
our biological systems, display brilliant anticancer properties
(Abdel-Fattah and Ali, 2018; Patil and Kim, 2017; Bisht and
Rayamajhi, 2016; Hassanien et al., 2018). From then on, a
high end-research has been conceded worldwide to develop
MNPs and nanocomposites for the treatment of different can-
cers including human CRC.
In addition to the wide applicability of nanomaterials in
catalysis and environmental issues, in recent times they also
have been observed to exhibit interesting biomedical applica-
tions in tissue engineering, photoablation therapy, bioimaging,
hyperthermia, medicinal therapeutics (McNamara and Tofail,
2016; McNamara et al., 2013; McNamara and Tofail, 2015).
Due to nano-dimensions, NPs can easily surpass the cell bar-
rier and also due to high surface area they are used as excellent
carriers of different hydrophobic and hydrophilic drugs, bio-
molecules like vaccines, hormones etc to different administra-
tions (Issa et al., 2013; Baygar and Ugur, 2017;
Shanmugasundaram et al., 2013; Zou et al., 2015;
Karamipour et al., 2015; Jia et al., 2012; Tansık et al., 2014).The NPs facilitate this delivery process by stimulating the drug
and also stabilizing them to reach the target cell (Surendra
et al., 2014; Sabale et al., 2015). Some NPs function as sensors
in diagnosis of ailments, detection of DNA and antibodies
(Park et al., 2014; Govindaraju et al., 2015; Patra et al.,
2015; Aygün et al., 2020). Recently, surface engineered func-
tionalized NPs have been found to show remarkable anti-
cancer activities, in particular, the cancer of lung, prostate,
ovarian and leukemia (Manjunath and Joshi, 2019;
Sriramulu and Sumathi, 2017; Netala et al., 2016). Surface
designing of NPs using different biomolecules and organic
ligands have been an excellent idea in order to improve the
binding the drugs and other molecules and also to target the
antibodies in the effective treatment of cancers.
Chitosan is a naturally occurring polymer with several elec-
tron rich polar functional groups like amino (NH2) and hydro-
xyl (OH) that used very well for synthesis and stabilizing of
various metal nanoparticles (Karthikeyan et al., 2020; Khan
et al., 2020). These very features of the functionalized NPs
have encouraged us to design and demonstrate a novel Cu
(II) immobilized chitosan (CS) modified-magnetite nanoparti-
cles (Fe3O4/CS/Cu(II)). The biopolymer (CS) was exploited to
create a shell over the pre-synthesized Fe3O4 NPs. Glutaralde-
hyde to use in this protocol to build a compact imino bridged
structure between the successive layers of CS. The super polar
environment (OH, NH2 groups) as created was subsequently
used to bind the incoming Cu (II) ions affording the nanocom-
posite. Now, towards the bio-applications, we employed the
as-architectured material to study the cytotoxicity against lung
cancer cell line though an MTT assay. Interestingly, we
acquired outstanding potential of the material as an unconven-
tional formulation towards the treatment of lung cancer.
2. Experimental
2.1. Materials and apparatus
All the reagents were purchased from Aldrich and Merck and
were used without any purification. CS, copper nitrate, sodium
hydroxide and all the other chemicals were purchased from
Sigma-Aldrich. In instrumental section, the particle size, mor-
phology and atomic mapping analysis of the nanomaterial was
investigated using a FESEM-TESCAN MIRA3 microscope
equipped with EDX. The crystalline structures of the samples
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ker D8 Advance diffractometer with CuKa radiation at 40 kV
and 20 mA. Fourier transform infrared (FT-IR) spectra were
recorded with a Perkin Elmer 65 spectrometer in the range
of 400–4000 cm1. Transmission electron microscopy (TEM)
analysis was performed on a Phillips CM10 microscope at an
accelerating voltage of 200 kV. Magnetization measurements
were carried out on a BHV-55 vibrating sample magnetometer
(VSM).
2.2. Preparation of Fe3O4 NPs
Its prepared according the literature Karthikeyan et al. (2020)
with some modification. Magnetite nanoparticles (Fe3O4) were
prepared by stirring FeSO4_s7H2O (2.1 g) and FeCl3_s6H2O
(3 g) in water (100 mL) at 80 C for 30 min. Then, 5 mL of
anhydrous ammonia was added into the reaction medium
and the mixture was stirred at 80 C for 30 min. Afterwards,
Fe3O4 was separated, washed with water to neutrality and
dried at 50 C for 12 h.
2.3. Preparation of Fe3O4/CS/Cu(II) nanocomposite
0.5 g Fe3O4 NP were dispersed in 50 mL deionized water. A
30 mL homogeneous mixture of chitosan (98% deacetylated,
4.3542  104 g/mol) in acetic acid solution (0.2 g CS in
50 mL 1% HOAc) was added to the dispersion. The resulted
solution was stirred vigorously and subsequently a glutaralde-
hyde aqueous solution (5 wt%, 10 mL) was added drop by
drop and stirred for 60 min at 50 C. The solid sample was col-
lected by external magnet, washed with ethanol for several
times to remove residual impurities and then left to dry at
60 C for 24 h affording a brown-colored solid. In the final
step, 0.5 gm of Fe3O4/CS composite was dispersed in
100 mL H2O by ultrasonication for 20 min. Subsequently, an
aqueous solution of Cu(NO3)2 (1 mmol in 20 mL H2O) was
added to reaction mixture and stirred for 5 h at 25 C. Then,
the mixture was cooled and the final material Fe3O4/CS/Cu
(II) nanocomposite were collected using a magnet. Subse-
quently, they were washed with distilled water and dried at
ambient temperature. The Cu load was 0.23 mmol/g as was
determined by ICP-OES.
2.4. Determination of antioxidant property of Fe3O4/CS/Cu(II)
nanocomposite
The DPPH method is a common method for the assessment of
the antioxidant activity of plant species and metallic nanopar-
ticles. It is based on trapping the free radicals of the material,
called DPPH, using antioxidant agents which reduce the
absorption rate at 520 nm wavelength. When the DPPH solu-
tion is mixed with a material that can donate hydrogen atom,
radical resuscitation is formed, which is followed by color
reduction. This reaction eliminates the purple color; whose
index is the formation of an absorption band at 520 nm
(Mahdavi et al., 2019).
To determine the radical scavenging activity of the Fe3O4/
CS/Cu(II) nanocomposite, 1 mL of 50 mm DPPH wascombined with 1 mL of variable concentrations (0–1000 mg/
mL) of Fe3O4/CS/Cu(II) nanocomposite. Then, they were
transferred to the 37 C for 1 h. The samples absorption rate
was determined at 520 nm by a spectrophotometer, and the
antioxidant activity was calculated by the below formula:
Inhibition %ð Þ ¼ SampleA:
ControlA:
x100
The blank sample contained 1 mL methanol and 1 mL
Fe3O4/CS/Cu(II) nanocomposite, and a sample of 1 mL
DPPH and 2 mL of Fe3O4/CS/Cu(II) nanocomposite with
the applied concentrations was regarded as the negative con-
trol (Mahdavi et al., 2019).
Calculation of half-maximal inhibitory concentration
(IC50) is a suitable method for comparison of the activity of
pharmaceutical materials. In this method, the measurement
and comparison criterion is the concentration in which 50%
of the final activity of the drug occurs. In this experiment,
the IC50 of various repeats is estimated and compared with
the IC50 of BHT, which is introduced as the antioxidant activ-
ity index. The closer is the obtained value to the IC50 of BHT,
the stronger is the antioxidant activity of the material. The
graph of the IC50 of the extract was produced by drawing
the percent inhibition curve versus the extract concentration.
First, three stock samples with variable concentrations (0–10
00 mg/mL) of Fe3O4/CS/Cu(II) nanocomposite were prepared.
Then, a serial dilution was prepared from each sample, and
IC50 of the above samples was measured separately, following
which their mean was calculated. BHT, with different concen-
trations, was considered positive control. All experiments were
performed in triplicate (Mahdavi et al., 2019).
2.5. Determination of anti-human lung cancer effects of Fe3O4/
CS/Cu(II) nanocomposite
The human lung cancer cell lines (Lung well-differentiated
bronchogenic adenocarcinoma: HLC-1, Lung moderately dif-
ferentiated adenocarcinoma: LC-2/ad, and Lung poorly differ-
entiated adenocarcinoma: PC-14) and the normal cell line
(HUVEC) in the MTT assay were used as follows. They were
then cultured as a monolayer culture in 90% RPMI-1640 med-
ium and 10% fetal serum and supplemented with 200 mg/mL
streptomycin, 125 mg/mL penicillin, and 8 mg/mL ampho-
tericin B. The culture was then exposed to 0.5 atmospheric car-
bon dioxide at 37 C, on which the tests were performed after
at least ten successful passages. MTT assay a method used to
investigate the toxic effects of various materials on various cell
lines, including non-cancer and cancer cells. To evaluate the
cell toxicity effects of the compounds used in this research,
the cells were transferred from the T25 flask to the 96-well
flasks. In each cell of the 96-cell flasks, 7000 cells of cancer
and fibroblast cell lines were cultured, and the volume of each
cell was eventually increased to 100 mL. Before the treatment
of the cells in the 96-well flak, the density of cells was increased
to 70%, so the 96-well flasks were incubated for 24 h to obtain
the cell density of 7  103. Next, the initial culture medium was
discarded, and variable concentrations (0–1000 mg/mL) of
Fe3O4/CS/Cu(II) nanocomposite were incubated at 37 C
and 0.5 CO2 for 24, 48, and 72 h. Then, 20 mL MTT was added
4 Z. Shi et al.to each well after a certain amount of time. Next, 100 mL
DMSO solvent was added to each well. They were then kept
at room temperature for 25 min and read at 490 and 630 nm
by a microtitre plate reader (Mahdavi et al., 2019).
The cell lines were treated with the hydroalcoholic extract
(1.25 mg/mL), which inhibited about 20% of the cell growth.
Annexin/PI method was used to determine the apoptosis level
in the treated and control cell lines using a flow cytometry
machine. To perform experiment, the cell lines were treated
with a variable concentrations (0–1000 mg/mL) of Fe3O4/CS/
Cu(II) nanocomposite for 24 h. Cells were irrigated with
phosphate-buffered saline (PBS). After centrifugation, buffer
binding was added to the obtained precipitate. Then, 5 mL
Annexin V dye was added and incubated for 15 min at
25 C. Cells were washed with the binding solution, following
which 10 mL PI dye was added. Finally, cell analysis was done
by a flow cytometry machine according to the below formula:
Cellviabilityð%Þ ¼ SampleA:
ControlA:
x100Fig. 1 Schematic fabrication of magne3. Results and discussion
3.1. Analysis of catalytic characterization data
After the post-grafting synthesis of Fe3O4/CS/Cu(II)
nanocomposite (Fig. 1), the physicochemical characteristics
and structural morphology were thoroughly studied using var-
ious analytical techniques like FT-IR, FE-SEM, EDX, elemen-
tal mapping, TEM, VSM, XPS, XRD and ICP-AES. Fig. 2
represents the FT-IR spectrum of the final nanocomposite
and its two precursor components in a single frame in order
to justify the structure. Fig. 2a shows the characteristic peaks
of Fe3O4 at 584 and 632 cm
1 attributed to Fe-O stretching
vibration of spinel structure. The representative peaks of chi-
tosan is shown in Fig. 2b, being appeared at 1033 cm1,
1385 cm1, 1616 cm1, 1739 cm1 and 3400–3500 cm1, corre-
sponding to C–N, C–O stretching, N-H bending, C = O and
O-H stretching vibrations respectively. In the spectrum of
Fe3O4/CS/Cu(II), the previous two components have been evi-tic Fe3O/CS/Cu(II) nanocomposite.
Fig. 2 FT-IR spectra of a) Fe3O4, b) CS and c) Fe3O4/CS/Cu(II) nanocomposite.
Fig. 3 FESEM image of Fe3O4/CS/Cu(II) nanocomposite.
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dates the unified and stable structure being formed with those
parts. The imino bonds (C = NH) formed during intermolec-
ular cross-linking can be observed at 1633 cm1. The deviation
in vibrations in the final material is anticipated due to strong
chelation with Cu NPs with the organofunctions.
FE-SEM analysis of Fe3O4/CS/Cu (II) NPs was carried out
to resolve its surface morphology, texture and particle size
(Fig. 3). It displays the quasi-spherical nano-dimensional par-
ticle units of mean particle size 25–35 nm. From close vicinity,
a thin continuous layer of CS over the core Fe3O4 can be iden-
tified. The aggregation of particles can be adjudged due to
manual sample preparation. An EDX instrument equipped
with the FESEM was used to ascertain the elementalcomposition of Fe3O4/CS/Cu (II) NPs (Fig. 4). The EDX pro-
file clearly shows the presence of Fe, Cu, C, N and O as the
constituting elements. As the sample is Au coated during anal-
ysis, it appears in the profile by default. C, N and O validates
the successful surface functionalization with CS. Now, the
results of EDX analysis was further confirmed by elemental
mapping study. A sectional scanning of SEM image reveals
the distribution of the comprising elements, being represented
in Fig. 5. The colored dots signify the corresponding atoms
which are uniformly spread over the whole surface.
The intrinsic structural features of the Fe3O4/CS/Cu(II)
nanocomposite are demonstrated though TEM analysis
(Fig. 6). The particles are roughly globular and within the size
range of 15–20 nm, being compatible with the FESEM results.
However, the surface functionalization could not be detected
from the image.
Magnetic properties of the Fe3O4/CS/Cu(II) nanocompos-
ite were appraised by VSM analysis. When a variable magnetic
field (20 kOe to +20 kOe) was applied on the material at
300 K, a hysteresis curves was obtained, being shown in
Fig. 7. It clearly denotes the superparamagnetic nature of the
material having magnetization saturation (Ms) value of 32.6.
Due to surface coating by the non-magnetic CS, Ms value is
observed low as compared to standard unmodified ferrite NPs.
Electronic environment, binding energy and oxidation
states of the active species in the material was ascertained by
XPS technique (Fig. 8). The 2p region of Cu splits up into
two spin-orbit components, namely, 2p3/2 and 2p1/2 and the
corresponding binding energies obtained from the nanocom-
posite was compared with the standard peak positions. The
two sharp peaks are observed at 933.61 eV and 943.12 eV
respectively indicating that Cu is in the formal +2 valance
state (Baygar and Ugur, 2017).
Fig. 4 EDX pattern of Fe3O4/CS/Cu(II) nanocomposite.
Fig. 5 Elemental mapping of Fe3O4/CS/Cu(II) nanocomposite,




















Applied Field (Oe) 
Fig. 6 TEM images of Fe3O4/CS/Cu(II) nanocomposite.
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Fig. 7 VSM analysis of Fe3O4/CS/Cu(II) nanocomposite.
Fig. 9 XRD patterns of (a) Fe3O4 and (b) Fe3O4/CS/Cu(II)
nanocomposite.
Cu immobilized on chitosan-modified iron oxide magnetic nanoparticles 7Finally, the crystallinity and phase structure of the Fe3O4/
CS/Cu(II) nanocomposite were determined by XRD analysis.
In Fig. 9, the diffraction peaks of bare Fe3O4 was compared
to the final material. As can be seen from Fig. 9a, the charac-
teristic peaks of Fe3O4 NPs appears at 2h= 30.6, 36.2, 43.7,
54.1, 57.4 and 63.5 due to diffraction on the (220), (311),
(400), (422), (511) and (440) planes (JCPDS No. 19-0629).
In the XRD profile of Fe3O4/CS/Cu(II), all the very peaks of
Fe3O4 NPs are present indicating the un-deformed coreFig. 8 XPS scan in the Cu 2p region fstructure even after post-modifications. The initial broad
region till 20 are contributed from CS. Additionally, the weak
diffraction peaks at 2h = 43.2, 50.5 and 74.4 correspond to
the (111), (200) and (220) planes of crystalline Cu phases
(JCPDS No.04–0784).or Fe3O4/CS/Cu(II) nanocomposite.
8 Z. Shi et al.3.2. Antioxidant, cytotoxicity and anti-human lung cancer
potentials of Fe3O4/CS/Cu(II) nanocomposite
In this study, the concentration-dependent DPPH radical scav-
enging effect of Fe3O4/CS/Cu(II) nanocomposite was analyzed
with respect to a standard molecule (BHT). The interaction
between Fe3O4/CS/Cu(II) nanocomposite and DPPH might
have occurred by transferring electrons and hydrogen ions
(Mahdavi et al., 2019). The scavenging capacity of theFig. 10 The antioxidant properties of Fe3O4,








IC50 against DPPH – 162 230Fe3O4/CS/Cu(II) nanocomposite and BHT at different con-
centrations, expressed in terms of percentage inhibition, has
been plotted in Table 1 and Fig. 10. The corresponding IC50
values of BHT and Fe3O4/CS/Cu(II) nanocomposite were
found 230 and 162 lg/mL, respectively.
In the recent research, the treated cells with several concen-
trations of the present of Fe3O4 and Fe3O4/CS/Cu(II)
nanocomposite were examined by MTT test for 72 h regarding
the cytotoxicity properties on HLC-1, LC-2/ad, and PC-14.
The absorbance rate was determined at 545 nm, which indi-
cated extraordinary viability on HLC-1, LC-2/ad, and PC-14
cell line even up to 1000 lg/mL nanocomposites (Table 2,
Fig. 11, Scheme 1). The results showed, the viability of them
reduced dose-dependently in the presence of Fe3O4/CS/Cu(II)
nanocomposite. The IC50 of Fe3O4/CS/Cu(II) nanocomposite
were 252, 233, and 128 mg/mL against HLC-1, LC-2/ad, and
PC-14 cell line, respectively (Table 2, Fig. 11, Scheme 1).nanocomposite, and BHT against DPPH.
Fig. 11 The anti-human lung adenocarcinoma properties of
Fe3O4 and nanocomposite against HLC-1 (a), LC-2/ad (b), and














Scheme 1 The cytotoxicity effects of Fe3O4 and na
Table 2 The IC50 of Fe3O4 and nanocomposite in the anti-





IC50 against MCF7 – 252
IC50 against Hs 578Bst – 233
IC50 against Hs 319.T – 128
IC50 against HUVEC 813 –
Cu immobilized on chitosan-modified iron oxide magnetic nanoparticles 9The anticancer potentials of Fe3O4/CS/Cu(II) nanocom-
posite against human lung cancer cell lines are linked to their
antioxidant properties. Several different studies have
revealed the strong antioxidant materials such as Cu and
Fe nanoparticles significantly reduces the volume of tumors
by removing free radicals (Mahdavi et al., 2019;
Beheshtkhoo et al., 2018; Sangami and Manu, 2017). Our
successful effort in exploiting Fe3O4/CS/Cu(II) nanocompos-
ite in lung cancer studies will definitely enlighten the future
studies in this arena.
4. Conclusions
In summary, we demonstrate the synthesis of Fe3O4/CS/Cu
(II) nanocomposite by post-synthetic coordinating Cu(II)
ions over chitosan modified magnetic nanoparticles. The
material was characterized using several advanced physico-
chemical methods. FESEM and TEM analysis justified the
grafting of CS over the core ferrite NPs. The incoming Cu
species was in ionic +2 state, as confirmed from XPS anal-
ysis. XRD analysis validated the united crystalline nanocom-
posite with all its possible characteristic diffraction peaks.
The nanocomposite was also explored biologically in the
antioxidant and anticancer assays. In the cytotoxicity and
anti-human lung studies, the nanocomposite was treated to
lung cancer cell lines following MTT assay. The cell viability
of malignant lung cell line reduced dose-dependently in the
presence of Fe3O4/CS/Cu(II) nanocomposite. IC50 values
of the nanocomposite were observed to be 915.22 lg/mL
against lung well-differentiated bronchogenic adenocarci-
noma (HLC-1), lung moderately differentiated adenocarci-
noma (LC-2/ad), and lung poorly differentiated
adenocarcinoma (PC-14) cell lines. The outstanding results
showed by the developed nanocomposite, could be highly













nocomposite against normal (HUVEC) cell line.
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